Intensity Therapeutics, Inc. (INTS) Net earnings per share growth forecast for next year
The development of cancer immunotherapy is independent of economic cycles, as demand for tumor treatment remains stable. Intensity Therapeutics (INTS) currently prices in this trend through its projected EPS growth for the coming year, where the parameter equals 39.60. The project relies on transparent INT230-6 tests and management expertise; however, financial stability is currently based on investments, as operating cash flow has not yet been established.
Metric breakdowns and analytics for Intensity Therapeutics, Inc. (INTS)
- price and consensus price forecast:
- market capitalization details:
- company book value details:
- company liabilities and liquidity data:
Debt to Equity Intensity Therapeutics|INTS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Intensity Therapeutics Inc|INTS - Company Total Indebtedness|Debt to Book Value Intensity Therapeutics|INTS - Amount of Long-Term Liabilities|Company Short-Term Debts Intensity Therapeutics|Quick Ratio intensitytherapeutics.com
- earnings and market ratios statistics:
INTS - Company Net Income|Expected Profit Intensity Therapeutics|INTS - Company Value to Net Income|Forward P/E Multiple Intensity Therapeutics Inc|INTS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics|INTS - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Intensity Therapeutics|INTS - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth intensitytherapeutics.com|INTS - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Intensity Therapeutics
Analysis of all company metrics:Intensity Therapeutics
The scaling of intratumoral drugs by Intensity Therapeutics (INTS) activates operating leverage, allowing revenue to effectively offset R&D capital expenditures. This metric aggregates expert earnings forecasts for the upcoming period, filtering out short-term volatility to identify the true profitability trend. The positive vector of this forward-looking net income trend assessment confirms the resilience of the business model and the reduction of liquidity risks as product lines expand.
Direct competitors
Net earnings per share growth forecast for next year ImmunityBio Corp|Expected earnings per share growth for next year Immunocore Corp (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics (JANX)|Expected earnings per share growth for next year arcusbio.com RCUS|Zymeworks - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Inc TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (Immatics Biotechnologies) - Projected earnings per share growth rate for next year|Xencor, Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year compasstherapeutics.com (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year IPHA (Innate Pharma, S.A.)|Projected earnings per share increase next year PYXS|Earnings growth forecast for next year CGEN (Compugen)|Expected earnings per share trend next year IOBT|Sutro Biopharma - Earnings growth forecast for next year|Expected net earnings per share growth next year MiNK Therapeutics Inc.|werewolftx.com (HOWL) - Net earnings per share growth forecast for next year|Immix Biopharma - Expected earnings per share trend next year|ALXO (ALX Oncology Holdings) - Earnings growth forecast for next year|Earnings growth forecast for next year cuebiopharma.com|Net earnings per share growth forecast for next year PDS Biotechnology (PDSB)|SONN: Net earnings per share change forecast for next year|MAIA Biotechnology Inc - Expected earnings per share growth for next year|Liminatus (LIMN) - Expected net earnings per share growth next year|Lava Tx - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year nextcure.com NXTC|leaptx.com (LPTX) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year SNSE|Expected earnings per share growth for next year TOVX|GRTS (Gritstone Bio) - Projected earnings per share increase next year|Earnings growth forecast for next year KA|NEXI - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Turnstone Biologics Corp. TSBX|VCNX: Projected earnings per share growth rate for next year|HARP - Net earnings per share growth forecast for next year
